Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Times Interest Earned (2020 - 2025)

Apellis Pharmaceuticals has reported Times Interest Earned over the past 6 years, most recently at -$4.71 for Q4 2025.

  • Quarterly results put Times Interest Earned at -$4.71 for Q4 2025, down 155.77% from a year ago — trailing twelve months through Dec 2025 was $1.25 (up 222.27% YoY), and the annual figure for FY2025 was $1.25, up 222.26%.
  • Times Interest Earned for Q4 2025 was -$4.71 at Apellis Pharmaceuticals, down from $19.79 in the prior quarter.
  • Over the last five years, Times Interest Earned for APLS hit a ceiling of $241.84 in Q4 2021 and a floor of -$56.09 in Q3 2021.
  • Median Times Interest Earned over the past 5 years was -$12.01 (2022), compared with a mean of $0.67.
  • Peak annual rise in Times Interest Earned hit 1686.14% in 2021, while the deepest fall reached 311.25% in 2021.
  • Apellis Pharmaceuticals' Times Interest Earned stood at $241.84 in 2021, then crashed by 108.77% to -$21.2 in 2022, then surged by 305.21% to $43.51 in 2023, then crashed by 80.57% to $8.45 in 2024, then crashed by 155.77% to -$4.71 in 2025.
  • The last three reported values for Times Interest Earned were -$4.71 (Q4 2025), $19.79 (Q3 2025), and -$2.98 (Q2 2025) per Business Quant data.